Novel N-substituted sophoridinol derivatives as anticancer agents

European Journal of Medicinal Chemistry

Volumn 81, Issue , 2014, Pages 95-105

  Bi, Chong Wen ^a   Zhang, Cai Xia ^a   Li, Ying Hong ^a   Tang, Sheng ^a   Deng, Hong Bin ^a   Zhao, Wu Li ^a   Wang, Zhen ^a   Shao, Rong Guang ^a   Song, Dan Qing ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Antiproliferative; Sophoridinic acid; Sophoridinol; Structure activity relationship; Topoisomerase I

Indexed keywords

12 N 2 CHLOROBENZYLSOPHORIDINOL; 12 N 2 FLUOROBENZYLSOPHORIDINOL; 12 N 2 FURFURYLSOPHORIDINOL; 12 N 2 PHENETHYLSOPHORIDINOL; 12 N 3 FLUOROBENZYLSOPHORIDINIC ACID; 12 N 3 FLUOROBENZYLSOPHORIDINOL; 12 N 4 CHLOROBENZYLSOPHORIDINOL; 12 N 4 FLUOROBENZYLSOPHORIDINOL; 12 N 4 METHYLBENZYLSOPHORIDINOL; 12 N 4 PICOLYLSOPHORIDINOL; 12 N BENZYLSOPHORIDINOL; 12 N BUTYLSOPHORIDINOL; 12 N ISOBUTYLSOPHORIDINIC ACID; 12 N ISOBUTYLSOPHORIDINOL; 12 N NEOPENTYLSOPHORIDINOL; 12 N PROPYLSOPHORIDINIC ACID; 12 N PROPYLSOPHORIDINOL; ANTINEOPLASTIC AGENT; METHYL 12 N 2 FLUOROBENZYLSOPHORIDINATE; METHYL 12 N 2 FURFURYLSOPHORIDINATE; METHYL 12 N 3 CHLOROBENZYLSOPHORIDINATE; METHYL 12 N 3 FLUOROBENZYLSOPHORIDINATE; METHYL 12 N 4 BROMOBENZYLSOPHORIDINATE; METHYL 12 N 4 CHLOROBENZYLSOPHORIDINATE; METHYL 12 N 4 FLUOROBENZYLSOPHORIDINATE; METHYL 12 N 4 PICOLYLSOPHORIDINATE; METHYL 12 N ISOBUTYLSOPHORIDINATE; METHYL 12 N PROPYLSOPHORIDINATE; SOPHORIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; QUINAZOLINE DERIVATIVE; SOPHORIDINOL; TOP1 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATOM; BREAST CANCER CELL LINE; CANCER CELL LINE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COLON CANCER; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME INHIBITION; EVALUATION STUDY; GLIOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC 50; LIVER CANCER CELL LINE; LUNG CANCER CELL LINE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MELTING POINT; NASOPHARYNX CANCER; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HCT116 CELL LINE; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAVENOUS DRUG ADMINISTRATION; KB CELL LINE; MCF 7 CELL LINE; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HEP G2 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; KB CELLS; MALE; MCF-7 CELLS; MICE; MICE, INBRED ICR; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE I INHIBITORS;

EID: 84900480683     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.04.069     Document Type: Article

References (21)

1. X.M. Li, Y.G. Wu, D.X. Pan, L.K. Wu, Y.H. Yu, A.H. Zhang, S.L. Chen, Z.Z. Guan, and X.Y. Yang Chin. J. New Drugs 08 2006 654 657
2. B. Zhao, Q. Wang, J. Liu, W.M. Xiong, Y.J. Li, X.L. Xie, J.G. Wang, CN Patent CN103191108A, 2013.
3. B. Zhao, Q. Wang, J. Liu, W.M. Xiong, Y.J. Li, X.L. Xie, C.L. Xie, CN Patent CN103191107A, 2013.
4. L. Zhang, W.J. Fan, X.H. Fan, and T. Tang Chin. J. Interv. Radiol. 2 2008 247 251
5. S. Huang, W. Fan, P. Liu, and J. Tian Zhongguo Zhong Yao Za Zhi 36 2011 3198 3202
6. H.F. Zhuang, J.X. Ren, Y.H. Zhou, X.Y. Chen, and Y.F. Wu Zhongguo Zhong Yao Za Zhi 21 2012 1013 1015
7. Y.Z. Ji, G.M. Liu, and R.J. Hu Shizhen Guo Yi Guo Yao 17 2006 986 989
8. B.G. Zhou, G. Su, D.Q. Ma, J.Z. Sun, Y.Z. Fan, and Y.C. Hao Tumour 23 2003 197 201
9. Y. Yang, Z.G. Zheng, M. Ji, and W.Y. Hua Yao Xue Jin Zhan 25 2001 152 156
10. G. Hong, and P.X. Liu Chin. Tradit. Herb. Drugs 5 2005 783 788
11. X. Li, W.L. Zhao, J.D. Jiang, K.H. Ren, N.N. Du, Y.B. Li, Y.X. Wang, C.W. Bi, R.G. Shao, and D.Q. Song Bioorg. Med. Chem. Lett. 18 2011 5251 5254
12. L.M. Gao, S. Tang, Y.X. Wang, R.M. Gao, X. Zhang, Z.G. Peng, J.R. Li, J.D. Jiang, Y.H. Li, and D.Q. Song ChemMedChem 9 2013 1545 1553
13. N.N. Du, Z.G. Peng, C.W. Bi, S. Tang, Y.H. Li, J.R. Li, Y.P. Zhu, J.P. Zhang, Y.X. Wang, J.D. Jiang, and D.Q. Song PLoS One 8 2013 e58675
14. V. Aureggi, V. Franckevilius, M.O. Kitching, S.V. Ley, D.A. Longbottom, and A.J. Oelke Org. Synth. 85 2008 72 87
15. N.N. Du, X. Li, Y.P. Wang, F. Liu, Y.X. Liu, C.X. Li, Y.X. Wang, J.D. Jiang, and D.Q. Song Bioorg. Med. Chem. Lett. 21 2011 4732 4735
16. G.Q. Hu, G.Q. Wang, N.N. Duan, X.Y. Wen, T.Y. Cao, S.Q. Xie, and W.L. Huang Acta Pharm. Sin. B 2 2013 312 317
17. H. Jin, K. Ren, H.W. He, X. Liu, D.Q. Song, and R.G. Shao Anticancer Drug 21 2010 372 380
18. G. Pöch, S. Vychodil-Kahr, and E. Petru Int. J. Clin. Pharmacol. Ther. 37 1999 189 192
19. X.K. Deng, W. Yin, W.D. Li, F.Z. Yin, X.Y. Lu, X.C. Zhang, Z.C. Hua, and B.C. Cai J. Ethnopharmacol. 106 2006 179 186
20. Y.B. Li, W.L. Zhao, Y.X. Wang, C.X. Zhang, J.D. Jiang, C.W. Bi, S. Tang, R.X. Chen, R.G. Shao, and D.Q. Song Eur. J. Med. Chem. 68 2013 463 472
21. C.H. Tseng, Y.L. Chen, P.J. Lu, C.N. Yang, and C.C. Tseng Bioorg. Med. Chem. 16 2008 3153 3162